- All > Medicine Access and Rational Use > Pricing
- All > Medicine Access and Rational Use > Rational Use
- All > Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Keywords > antiviral therapy
- Keywords > chronic diseases
- Keywords > hepatitis C
- Keywords > hepatitis C (HCV) medicines technology and market landscape
- Keywords > hepatitis C (HCV) – prevention and control, diagnosis and drug therapy
- Keywords > HIV/HCV coinfection
- Keywords > new medicines - prices, costs and affordability
- Keywords > patents
- Keywords > prices / pricing policy
- Keywords > therapeutic guidelines
(2017; 140 pages)
Unitaid was created in 2006 to facilitate access to commodities needed to treat human immunodeficiency virus (HIV), tuberculosis (TB) and malaria. In 2013, Unitaid started looking at hepatitis C virus (HCV) in the context of HIV/HCV coinfections.
Unitaid has a mandate to work on HCV in the context of HIV coinfection. Through this mandate, Unitaid seeks to address market problems and, thus, to contribute to the goal of elimination of hepatitis C as a public health problem by 2030.
This landscape analysis provides an overview of the current state of technologies for the treatment of HCV, as well as of the market dynamics that affect access to HCV medicines. It will help identify potential opportunities for investment.
Following a brief description of the methodology, chapters 1–3 of the report provide a short overview of the public health problem of HCV infection, the global goals and the factors that affect uptake of new treatments. Chapter 4 summarizes current knowledge of the fast-evolving landscape of approved and pipeline HCV treatments, comparing each to the target profile for an optimally effective and scalable HCV treatment regimen. Chapter 5 provides an overview of the market dynamics associated with HCV treatments, including supply, demand and factors that affect the affordability, accessibility and uptake of the treatments.